...said it will voluntarily delist its shares from NASDAQ effective on about Aug. 27. *** Xtent Inc....

...30, Xtent had $10 million in cash and a six-month operating loss of $12 million. Xtent Inc....

...mm stent lengths. The company did not disclose when it expects to launch the system. Xtent Inc....

...treat coronary artery disease (CAD). Xtent plans to launch the product in Europe in 2H08. Xtent Inc....

...28). The trial enrolled 69 patients with long lesions and 31 patients with 2 lesions. Xtent Inc....

...events from 8 months to 2 years. Restenosis and late stent thrombosis rates were zero. Xtent Inc....

...patients with single focal, long or multiple lesions in the pilot European CUSTOM III trial. Xtent Inc....

...and 31 patients with 2 lesions. Data were presented at the EuroPCR meeting in Barcelona. Xtent Inc....

...BiolineRx (Tel Aviv:BLRX) 2/7/07 $49.9 $113.1 $89.9 -21% Oculus (OCLS) 1/24/07 $24.2 $91.4 $67.8 -26% Xtent...

...guidance. XOMA expects FY07 revenue to come in at $57.5-$60.5M, a 95-105% increase over FY06. Xtent...